1. These results confirm increased macrophage activation in inflammatory bowel disease and suggest functional heterogeneity within the intestinal macrophage population.

2. For inflammatory bowel disease the morbid risk varies with age.

3. With inflammatory bowel disease, the loss of protein through the gastrointestinal tract is also a contributory factor.

4. In our previous study, 34 monozygotic pairs with inflammatory bowel disease were found.

5. Recent evidence favours the idea that inflammatory bowel disease may be caused by mesenteric vasculitis.

6. Patients with gall stones or established inflammatory bowel disease were excluded.

7. Furthermore, cultured mononuclear cells isolated from inflammatory bowel disease mucosa spontaneously secrete large amounts of IgG.

8. Also in patients with inflammatory bowel disease antineutrophil cytoplasmic antibodies have been detected.

9. This case supports the theory that functional disturbances of the thymus may have a role in the pathogenesis of inflammatory bowel disease.

10. Pronounced changes have been found in gut neuropeptides in patients with inflammatory bowel disease.

11. The mode of action of 5ASA and 4ASA in inflammatory bowel disease is unknown.

12. One potential source for the increased values of reactive oxygen species in inflammatory bowel disease is the neutrophil.

13. Several different types of autoantibodies have been described in inflammatory bowel disease and primary sclerosing cholangitis.

14. While corticosteroids have an adverse effect on bone mass, this may be partly counterbalanced by improvement in the inflammatory bowel disease.

15. The rate of liver protein synthesis in patients with inflammatory bowel disease was 43% higher than the control group of patients.

16. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease.

17. The role of platelet activating factor blocker in the treatment of inflammatory bowel disease deserves investigation.

18. Another possibility is that the genetic regulation of the isotype response is different in the two populations of inflammatory bowel disease patients.

19. Nevertheless the absence of recurrence during long term follow up will be required to exclude underlying idiopathic inflammatory bowel disease.

19. is a online sentence dictionary, on which you can find good sentences for a large number of words.

20. However, Tsuchiya etal have described an association between thymic abnormalities and inflammatory bowel disease.

21. Ulcerative colitis and Crohn's disease are chronic, remitting and relapsing mucosal disorders, collectively known as inflammatory bowel disease.

22. With regard to the diagnosis in approximately 10% of inflammatory bowel disease patients with colonic involvement a definite distinction can not be made.

23. Little information is currently available on the role of interleukin 1 and tumour necrosis factor in inflammatory bowel disease.

24. New corticosteroid compounds with high topical and little systemic activity seem to offer great benefit to inflammatory bowel disease patients.

25. These results also question the rationale of using n3 polyunsaturated fatty acids in the treatment of inflammatory bowel disease.

26. The possible therapeutic effect of a specific receptor antagonist in inflammatory bowel disease remains to be evaluated.

27. This review examines the evidence that abnormal oxidative metabolism is of central importance to active inflammatory bowel disease.

28. A disturbance in immunoregulatory control has long been suspected to play a major role in the pathogenesis of inflammatory bowel disease.

29. Reports of invitro production of cytokines by peripheral or mucosal mononuclear cells in inflammatory bowel disease, however, conflict.

30. Tumour necrosis factor mRNA was detected in four of nine controls compared with 11/15 inflammatory bowel disease patients.

31. Design - Cross sectional population based survey of familial occurrence of chronic inflammatory bowel disease.

32. Rises in whole body turnover rates have also been seen in patients with inflammatory bowel disease.

33. Introduction Familial occurrence of chronic inflammatory bowel disease has been reported in several studies during the past decades.

34. Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease?

35. Sulfasalazine possesses both antiinflammatory and antibacterial properties and was mainly used to treat inflammatory bowel disease and rheumatoid arthritis.

36. Inflammatory bowel disease (IBD) predominantly affects the gastrointestinal system but it is associated with a large number of extraintestinal manifestations.

37. Early diagnosis and treatment is important for the patients with osteoporosis in inflammatory bowel disease.

38. Inflammatory bowel disease can also lead to inflammation of the lymphatics and lymphangiectasia through migration of inflammatory cells through the lymphatics.

39. Chronic diarrhea is usually related to functional disorders such as bowel syndrome or inflammatory bowel disease.

40. Inflammatory bowel disease(IBD) includes ulcerative colitis(UC) and Crohn's disease(CD). The pathophysiology mechanisms of the disease remains elusive.

41. OBJECTIVE:To investigate status quo of pharmacogenetics of inflammatory bowel disease (IBD), in order to provide some references for rational use of such kinds of drugs in the clinic.

42. Gastrointestinal disorders, such as inflammatory bowel disease and Crohn's disease.

43. Objective : To improve the therapeutic effect of inflammatory bowel disease ( IBD ).

44. Conclusion Early adverse reaction is the main cause of azathioprine premature discontinuation in inflammatory bowel disease.

45. Animal models inflammatory bowel disease can be induced by chemical, immunology, genetics and other access methods.

46. Inflammatory bowel disease such as ulcerative colitis and Crohn's disease may occur here.

47. We examined clinical, endoscopic, and pathologic data from 29 patients with isolated ileitis and no prior history of inflammatory bowel disease, and no colonic or upper gastrointestinal involvement.

48. Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment.

49. CONCLUSION: NF - κ B decoy ODNs will become a new gene drug for treating inflammatory bowel disease ( IBD ) .

50. Objective:To observe the efficacy and safety of Etiasa, a control released tablet of mesalazine, in treatment of inflammatory bowel disease(IBD) in comparison with salicylazosulfapyridine (SASP).

51. A high intake of polyunsaturated fat in the diet, while good for the heart, may lead to inflammatory bowel disease, say researchers.

52. Since then, other studies have found that when treated with worms, people with inflammatory bowel disease can improve and diabetic patients may return to normal blood-glucose levels.